Vaccines
5 March 2015
ORYX’ Therapeutic Vaccine MicOryx Successfully Completes Phase I/IIa Trial to Treat MSH-H Colorectal Cancer2 March 2015
Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases26 February 2015
Gradalis, Inc. Announces Initiation of a Phase 3 Registration Study for Vigil(TM) in Ovarian Cancer26 February 2015
ABIVAX Recruits First Patient in a Pivotal Phase IIb/III clinical trial with ABX203, a novel immunotherapy against chronic hepatitis B25 February 2015
GREER® Laboratories, Inc. Presents U.S. Grass Pollen Exposure Study Data at the 2015 AAAAI Annual Meeting25 February 2015
PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer24 February 2015
Viaskin(r) Data Presented at AAAAI Meeting Show Safety and Efficacy in the Treatment of Food Allergies20 February 2015
NewLink Genetics Corporation Announces Clinical Development Milestone Achieved With Merck for Ebola Vaccine Candidate13 February 2015
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC11 February 2015
Immune Design Announces First Patients Dosed in Phase 1 Clinical Trial of G100 Investigational Immuno-Oncology Agent9 February 2015
Aduro Meets Development Milestone in Immuno-Oncology Collaboration with Janssen for Treatment of Prostate Cance29 January 2015
BIOMAY AG REPORTS POSITIVE PHASE IIB DATA WITH THE INNOVATIVE 3RD GENERATION GRASS POLLEN ALLERGY VACCINE BM3224 January 2015
Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial24 January 2015
Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US23 January 2015
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence First-in-Human Clinical Trials of ADXS-HER223 January 2015
Prevenar 13®* Receives CHMP Positive Opinion For Prevention Of Vaccine-Type Pneumococcal Pneumonia in Adults20 January 2015
Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine12 January 2015
Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical TrialsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports